Last deal

$109M

Amount

Post-IPO Equity

Stage

12.08.2022

Date

3

all rounds

$449.5M

Total amount

date founded

Financing round

General

About Company
GreenLight Biosciences delivers high-quality RNA products quickly and at a lower cost than ever before.

Industry

Sector :

Subsector :

founded date

01.01.2008

Number of employees

Company Type

For Profit

Last funding type

Post-IPO Equity

IPO status

Private

Description

The company's proprietary cell-free RNA production platform enables the discovery and development of high-performing products for plant and life science applications, including crop management, plant protection, animal health, vaccine development, and pandemic preparation. GreenLight Biosciences collaborates with industry leaders to advance these areas and is committed to using the power of RNA to address global challenges such as pandemics, rare diseases, biodiversity, and climate change.
Contacts
Similar Companies
999
Pluton Biosciences

Pluton Biosciences

Pluton Biosciences uses Micromining to extract microbes from the soil and develop next-generation biosolutions.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Location

St. Louis, MO, USA

total rounds

3

total raised

$23.2M
Viridos

Viridos

Synthetic Genomics develops genomic-driven solutions for global energy and environmental challenges.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Financial Services, Genetics

Location

La Jolla, San Diego, CA, USA

total rounds

11

total raised

$202M

count Of Investments

1
Varigen

Varigen

Terra Bioforge is a biotechnology company that develops new technologies for capturing and expressing natural product pathways.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Location

Madison, WI, USA

total rounds

3

total raised

$555K
Boost Biomes

Boost Biomes

Boost Biomes is a California-based company that develops microbial products to sustainably improve food production and shelf-life.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Food and Beverage, Food Processing

Location

South San Francisco, CA, USA

total rounds

7

total raised

$9.2M
M&A Details
1

Acquired by

Fall Line Capital

announced date

30.05.2023

price

$45.5M

Financials

Funding Rounds
10
3

Number of Funding Rounds

$449.5M

Money Raised

Their latest funding was raised on 12.08.2022. Their latest investor Insud Pharma. Their latest round Post-IPO Equity

Date 
Funding Round 
Investors 
Money Raised 
Lead 
12.08.2022
11
$109M
03.02.2022
15
$125.5M
Morningside Venture Partners

Morningside Venture Partners

Morningside Venture Partners partners with talented entrepreneurs to develop the next wave of great companies.

Sector

Investment Banking and Brokerage Services

Subsector

Asset Managers and Custodians

Keywords

Venture Capital, Financial Services, Food and Beverage

Location

New York, NY, USA

count Of Investments

31
Co-Investors
Investors
30
2

Number of lead investors

30

Number of investors

Investor 
Lead 
Round 
Partners 
No
Post-IPO Equity
No
Post-IPO Equity
Insud Pharma

Insud Pharma

INSUD PHARMA is a pharmaceutical company that covers the entire value chain.

Sector

Pharmaceuticals and Biotechnology

Subsector

Pharmaceuticals

Keywords

Pharmaceuticals, Biotechnology, Manufacturing

Location

Madrid, Spain

count Of Investments

2
FTX Foundation

FTX Foundation

The FTX Foundation is a nonprofit organization that supports global health through grants and funding.

Sector

Health Care Providers

Subsector

Health Care Management Services

count Of Investments

1
Serum Life Sciences

Serum Life Sciences

Serum Life Sciences is a subsidiary of the Serum Institute of India that markets and distributes coronavirus disease vaccines.

Sector

Pharmaceuticals and Biotechnology

Subsector

Pharmaceuticals

Location

London, UK

count Of Investments

3
Natasha Poonawalla

Natasha Poonawalla

Natasha Poonawalla is a Executive Director of Serum Institute of India.

current job

Serum Institute of India Pvt. Ltd.
Serum Institute of India Pvt. Ltd.

People

Founders
4
Marta Ortega-Valle
Marta Ortega-Valle

Marta Ortega-Valle

Marta Ortega-Valle is the Co-founder & Chief Business Officer of GreenLight Biosciences.

current job

Greenlight Biosciences
Greenlight Biosciences

organization founded

1

Marta Ortega-Valle

Marta Ortega-Valle
Marta Ortega-Valle

Marta Ortega-Valle

Marta is a GreenLight co-founder and leads GreenLight’s Life Sciences business which includes development of vaccines and therapeutics leveraging GreenLight’s mRNA drug development and manufacturing technology platform. Since the firm’s creation, Marta has successfully led multi-million-dollar collaboration agreements with life science companies from definition to execution. Prior to joining GreenLight, she was entrepreneur-in-residence at Kodiak Venture Partners, where she started GreenLight with Andrey Zarur and Professor James Swartz. Marta holds an M.B.A. from Massachusetts Institute of Technology, Sloan Fellows Program at the Sloan School of Management, and a master’s in electrical engineering from ETSEIB (UPC) Engineering School of Barcelona.

current job

Greenlight Biosciences
Greenlight Biosciences

organization founded

1

Marta Ortega-Valle

James Swartz

Prof. Swartz, a leading expert in the field of cell-free protein synthesis, is a director and founder of Sutro Biopharma. He holds the James H. Clark Professorship in the School of Engineering at Stanford University and is a professor in the departments of bioengineering and chemical engineering. Prof. Swartz is a member of the National Academy of Engineering with over twenty years of industrial experience at Eli Lilly and Genentech prior to joining Stanford in 1998. He received his undergraduate degree in chemical engineering from the South Dakota School of Mines and his graduate degree from the Massachusetts Institute of Technology. Prof. Swartz is an author and a co-author on numerous scientific publications dealing with protein expression and advancement of cell-free protein production technology. "I am delighted to expand my involvement with Sutro through the appointment as scientific advisor," said Prof. Swartz. "Sutro has made tremendous progress within the past year, and the scientific advisory board will be tasked with helping to guide Sutro's management as they work to expand the company's proprietary pipeline as well as the projects with current and new partners."

current job

Sutro Biopharma
Sutro Biopharma

organization founded

1

James Swartz

Andrey Zarur
Andrey Zarur

Andrey Zarur

Andrey Zarur is the Co-Founder, President & CEO at Greenlight Biosciences. Andrey leads Kodiak's investment efforts in Life Technologies. He focuses on a broad array of opportunities in life sciences including molecular diagnostics, medical devices, biomaterials, and drug discovery platforms. He represents Kodiak on the boards of Allegro Diagnostics, Astadia, Fluxion Biosciences, Lumicell, and GreenLight Biosciences. Prior to joining Kodiak in 2006, Andrey was the Founder and CEO of BioProcessors (sold to Seahorse Biosciences). During his career as an entrepreneur, Andrey has been involved in the conception, founding, launching and operations of over a dozen startups in life sciences and sustainable technologies. In addition, he is an Overseer of the Museum of Science in Boston and a Senior Lecturer at the Massachusetts Institute of Technology. In 2005 he was elected as a Young Global Leader of the World Economic Forum.

current job

Greenlight Biosciences
Greenlight Biosciences

Andrey Zarur

Employee Profiles
38
Chetan Tadvalkar

Chetan Tadvalkar

Vice President, Enterprise Operations and Strategy

Amin Khan

Amin Khan

Chief Scientific Officer, Human Health R&D

Mark Singleton

Mark Singleton

SVP Technologies and External Innovation

Jennifer Raymond

SVP CMC & Manufacturing

Thomas Crampton

Thomas Crampton

SVP and Head of Corporate Affairs

Anthony Cataldo

Assistant general counsel, intellectual property

Charu Manocha

Charu Manocha

Chief People Officer

David Kennedy

David Kennedy

General Counsel

Activity

Recent News
2